Trial Profile
A phase 2, open label, randomized, active control study to find the optimal dose of P1101 by comparing antiviral activity, and safety across treatment groups in interferon naïve patients with chronic hepatitis B virus (HBV) infection.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 May 2018
Price :
$35
*
At a glance
- Drugs Ropeginterferon alfa-2b (Primary) ; Peginterferon alfa-2a
- Indications Hepatitis B
- Focus Pharmacodynamics
- 17 May 2018 New trial record
- 14 Apr 2018 Results presented at The International Liver Congress 2018